Skip to main content

#Mpox - Multi-country external #situation #report no. 60 published 8 December 2025 (#WHO, summary)

Image
By G.M.

 


{Summary}

Highlights   

• All clades of the monkeypox virus (MPXV) continue to circulate. 

- When mpox outbreaks are not rapidly contained and human-to-human transmission is not interrupted, there is a risk of sustained community transmission.  

• In October 2025, 44 countries, across all WHO regions, reported a total of 2501 new confirmed mpox cases, including 12 deaths (case fatality ratio [CFR] 0.5%). 

- About 75% of these cases were reported in the African Region. 

- All regions, apart from the South-East Asia Region observed a decline in confirmed cases in October, compared to September 2025.     

• Twenty-one countries in Africa have reported active transmission of mpox in the last six weeks (12 October – 23 November 2025), with 1734 confirmed cases, including 10 deaths (CFR 0.6%) reported during this period. 

- Countries reporting the highest number of cases in this period are the Democratic Republic of the Congo, Liberia, Ghana, Kenya and Uganda; with all of them showing a downward trend in cases in recent weeks. 

• One country, Mali, has reported mpox for the first time. 

- The case reported a recent history of travel to Guinea. 

- Genomic sequencing analysis is ongoing to determine the MPXV clade.  

• Greece has reported detection of clade Ib MPXV for the first time.   

• New imported cases of mpox due to clade Ib MPXV detected among travellers have been reported in Belgium, Germany, Greece, and the United Kingdom of Great Britain and Northern Ireland. 

• Since the last report, at least 15 cases of mpox due to clade Ib MPXV have been detected among individuals who self-identify as men who have sex with men.   

• Outside Africa, local transmission of clade Ib MPXV has been occurring in Italy, the Netherlands, Portugal and Spain, the United States of America and Malaysia. 

(...)

Source: 


Link: https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--60---8-december-2025

____

Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »